Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. (Q43041894)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

title

Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

David Jackson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Brendon Chua

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Paul Urquhart Cameron

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Lorena E. Brown

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

author name string

Anne Healy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Owen Stock

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Michael Rizkalla

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Weiguang Zeng

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Nina L Fowler

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

Eric J Gowans

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

Immunology & Cell Biology

16 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

16 December 2019

page(s)

67-72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12534949%20AND%20SRC:MED&resulttype=core&format=json

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

16 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

How viruses escape from cytotoxic T lymphocytes: molecular parameters and players

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Determinants of viral clearance and persistence during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Analysis of a successful immune response against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Analysis of successful immune responses in persons infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Hepatitis C virus core protein inhibits human T lymphocyte responses by a complement-dependent regulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

The metabolism of 3-chloro,- 3-bromo- and 3-iodoprpan-1,2-diol in rats and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Preparation and properties of totally synthetic immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Pimelautide or trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Protection of mice against SV40 tumours by Pam3Cys, MTP-PE and Pam3Cys conjugated with the SV40 T antigen-derived peptide, K(698)-T(708).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Activation of nuclear factor-kappaB in macrophages by mycoplasmal lipopeptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X

Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1711.2003.01133.X